Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4060-4066

  Vergote, Ignace B ^a   Garcia, Agustin ^d   Micha, John ^e   Pippitt, Charles ^h   Bendell, Johanna ⁱ   Spitz, Daniel ^j   Reed, Nicholas ^k   Dark, Graham ^l   Fracasso, Paula M ^o   Ibrahim, Emad N ^f   Armenio, Vincent A ^p   Duska, Linda ^o   Poole, Chris ^m   Gennigens, Christine ^b   Dirix, Luc Y ^c   Leung, Abraham C F ^g   Zhao, Carol ^g   Soufi Mahjoubi, Raoudha ^g   Rustin, Gordon ⁿ  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c Hospital Gasthuis Zusters Antwerpen (GZA)   (Belgium)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Gynecologic Oncology Associates   (United States)

^f Beaver Medical Group   (United States)

^g NEKTAR THERAPEUTICS   (United States)

^h PA   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

^j Palm Beach Institute   (United States)

^k BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^l FREEMAN HOSPITAL   (United Kingdom)

^m UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

ⁿ MOUNT VERNON HOSPITAL   (United Kingdom)

^o UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^p Sention   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CA 125 ANTIGEN; DOXORUBICIN; ETIRINOTECAN PEGOL; GEMCITABINE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; MACROGOL DERIVATIVE; PLATINUM DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONOPHARMACOLOGY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INTESTINE OBSTRUCTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PELVIC DISEASE; PELVIC HEMORRHAGE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEPSIS; SURVIVAL ANALYSIS; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE; UREMIA; VOMITING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84891940773     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.1278     Document Type: Article

References (25)

1. Siegal R, Naishadham D, Jemal A, et al: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Heintz AP, Odicino F, Maisonneuve P, et al: Carcinoma of the ovary: FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95:S161-S192, 2006 (suppl 1)
3. National Cancer Institute: Ovarian epithelial cancer treatment. http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial/HealthProfessional/page1/AllPages/Print
4. Markman M: Update on the utility of prognostic biomarkers in ovarian cancer. F1000 Med Rep 1:31, 2009
5. Thigpen JT, Alberts D, Birrer M, et al: Current challenges and future directions in the management of ovarian cancer: Proceedings of the First Global Workshop on Ovarian Cancer. Clin Ovarian Cancer Other Gynecol Malig 3:81-97, 2010
6. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193, 1997
7. Gordon AN, Granai CO, Rose PG, et al: Phase II study of liposomal doxorubicin in platinum and paclitaxel refractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100, 2000
8. Gordon AN, Tonda M, Sun S, et al: Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1-8, 2004
9. Monk BJ, Herzog T, Kaye S, et al: A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann Oncol 19:viii2, 2008 (suppl 8; abstr LBA4)
10. Pujade-Lauraine E, Paraiso D, Cure H, et al: Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): A GINECO study. Proc Am Soc Clin Oncol 21:18s, 2002 (abstr 829)
11. Slatter JG, Schaaf LJ, Sams JP, et al: Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of (14C) CPT-11 in cancer patients. Drug Metab Dispos 28:423-433, 2000
12. Eldon MA, Antonian L, Burton K, et al: NKTR-102, a novel pegylated-irinotecan conjugate, demonstrates improved pharmacokinetics with sustained exposure of irinotecan and its active metabolite. Presented at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007 (abstr P-0727)
13. Eldon MA, Antonian L, Staschen CM, et al: Anti-tumor activity and pharmacokinetics of NKTR-102, a novel pegylated-irinotecan conjugate, in irinotecan-resistant colorectal tumors implanted in mice. Presented at the 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007 (abstr P-0722)
14. Eldon MA, Staschen CM, Viegas T, et al: NKTR-102, a novel pegylated-irinotecan conjugate, results in sustained tumor growth inhibition in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN38 exposure. Presented at the 2007 American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007 (abstr C157)
15. Persson H, Antonian L, Staschen CM, et al: NKTR-102, a novel polyethylene glycol conjugate of irinotecan, has improved anti-tumor activity in three mouse xenograft models. Presented at the 2007 American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, October 22-26, 2007 (abstr C10)
16. Persson H, Barker T, Eldon M, et al: NKTR-102, a novel pegylated-irinotecan, has a superior acute safety, tolerability, and pharmacokinetic profile compared to irinotecan in rats and dogs. Presented at the 2008 American Association for Cancer Research Annual Meeting, San Diego, CA, April 12-16, 2008 (abstr 5742)
17. Persson H, Barker T, Eldon M, et al: NKTR-102, a novel pegylated-irinotecan, has an enhanced pharmacokinetic profile with reduced gastrointestinal and hematopoietic toxicity compared to irinotecan with repeat dosing in dogs. Presented at the 2008 American Association for Cancer Research Annual Meeting, San Diego, CA, April 12-16, 2008 (abstr 5741)
18. Hoch U, Masuoka L, Maslyar D, et al: NKTR-102 demonstrates nonclinical and phase 1 clinical anti-tumor activity in ovarian cancer. Presented at the European Cancer Organisation 15-European Society for Medical Oncology 34 Multidisciplinary Conference, Berlin, Germany, September 20-22, 2009 (abstr 8015)
19. Von Hoff DD, Jameson GS, Borad MJ, et al: First phase I trial of NKTR-102 (PEG irinotecan) reveals early evidence of broad anti-tumor activity in three schedules. Eur J Cancer 6:12, 2008 (suppl; abstr 595)
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
21. Rustin GJ, Vergote I, Eisenhauer E, et al: Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynaecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21:419-423, 2011
22. National Cancer Institute: Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events, version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov
23. Jameson GS, Hamm JT, Weiss GJ, et al: A multicenter, phase I, dose-escalation study to assess the safety, tolerability and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19:268-278, 2013
24. Vergote I, Finkler N, del Campo J, et al: Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 45:2324-2332, 2009
25. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63:89-93, 1996